NCT01449877View on ClinicalTrials.gov

Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Ocular Toxoplasmosis
Interventions
DRUG

Trimethoprim-Sulfamethoxazole

Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.

Trial Locations (1)

13083570

University of Campinas - Ophthalmology Department, Campinas

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Campinas, Brazil

OTHER

NCT01449877 - Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis | Biotech Hunter | Biotech Hunter